BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 21168458)

  • 21. Effect of radiation and ibuprofen on normoxic renal carcinoma cells overexpressing hypoxia-inducible factors by loss of von Hippel-Lindau tumor suppressor gene function.
    Palayoor ST; Burgos MA; Shoaibi A; Tofilon PJ; Coleman CN
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4158-64. PubMed ID: 15217953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
    Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
    Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor.
    Shang D; Liu Y; Yang P; Chen Y; Tian Y
    Urology; 2012 Apr; 79(4):966.e1-7. PubMed ID: 22341602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growth.
    Chen L; Xia G; Qiu F; Wu C; Denmon AP; Zi X
    Sci Rep; 2016 Sep; 6():32582. PubMed ID: 27581364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic deletion of the long isoform of the von Hippel-Lindau tumour suppressor gene product alters microtubule dynamics.
    Frew IJ; Smole Z; Thoma CR; Krek W
    Eur J Cancer; 2013 Jul; 49(10):2433-40. PubMed ID: 23541568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
    Blancher C; Moore JW; Robertson N; Harris AL
    Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.
    Zimmer M; Doucette D; Siddiqui N; Iliopoulos O
    Mol Cancer Res; 2004 Feb; 2(2):89-95. PubMed ID: 14985465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
    Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoxia-inducible factor-2α stabilizes the von Hippel-Lindau (VHL) disease suppressor, Myb-related protein 2.
    Okumura F; Joo-Okumura A; Nakatsukasa K; Kamura T
    PLoS One; 2017; 12(4):e0175593. PubMed ID: 28394947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.
    Carew JS; Esquivel JA; Espitia CM; Schultes CM; Mülbaier M; Lewis JD; Janssen B; Giles FJ; Nawrocki ST
    PLoS One; 2012; 7(1):e31120. PubMed ID: 22295124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor.
    Rankin EB; Tomaszewski JE; Haase VH
    Cancer Res; 2006 Mar; 66(5):2576-83. PubMed ID: 16510575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Downregulating hypoxia-inducible factor-2α improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma.
    He C; Sun XP; Qiao H; Jiang X; Wang D; Jin X; Dong X; Wang J; Jiang H; Sun X
    Cancer Sci; 2012 Mar; 103(3):528-34. PubMed ID: 22145922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
    Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.
    Turcotte S; Desrosiers RR; Beliveau R
    Am J Physiol Renal Physiol; 2004 Feb; 286(2):F338-48. PubMed ID: 14583436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular stomatitis virus: role of HIF in antiviral response.
    Hwang II; Watson IR; Der SD; Ohh M
    J Virol; 2006 Nov; 80(21):10712-23. PubMed ID: 16928739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic regulation of HIF-1α in renal cancer cells involves HIF-1α/2α binding to a reverse hypoxia-response element.
    Xu J; Wang B; Xu Y; Sun L; Tian W; Shukla D; Barod R; Grillari J; Grillari-Voglauer R; Maxwell PH; Esteban MA
    Oncogene; 2012 Feb; 31(8):1065-72. PubMed ID: 21841824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Action of hypoxia-inducible factor in liver and kidney from mice with Pax8-rtTA-based deletion of von Hippel-Lindau protein.
    Mathia S; Paliege A; Koesters R; Peters H; Neumayer HH; Bachmann S; Rosenberger C
    Acta Physiol (Oxf); 2013 Mar; 207(3):565-76. PubMed ID: 23384425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
    Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreased growth of Vhl-/- fibrosarcomas is associated with elevated levels of cyclin kinase inhibitors p21 and p27.
    Mack FA; Patel JH; Biju MP; Haase VH; Simon MC
    Mol Cell Biol; 2005 Jun; 25(11):4565-78. PubMed ID: 15899860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations.
    Li L; Zhang L; Zhang X; Yan Q; Minamishima YA; Olumi AF; Mao M; Bartz S; Kaelin WG
    Mol Cell Biol; 2007 Aug; 27(15):5381-92. PubMed ID: 17526729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.